WhatistheSymbol
Guerbet trades in the stock market under the ticker symbol of GBT. Search for the ticker of any public company above using the 'Get Ticker' search in red.

Who is Guerbet?


Warning: fopen(/home/whatist/public_html/symbol/cache/scraperDScache_getCompanyDetails_GBT) [function.fopen]: failed to open stream: Permission denied in /home/whatist/public_html/symbol/classes/class.cache.php on line 66
1,485 Employees
Last Reported Date: 08/1/14
Founded in 1901
Last €41.68 EUR
Change Today +0.87 / 2.13%
Volume 26.7K
As of 11:35 AM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

guerbet (GBT) Snapshot

Open
€41.00
Previous Close
€40.81
Day High
€42.39
Day Low
€41.00
52 Week High
09/11/14 - €45.52
52 Week Low
10/2/13 - €21.17
Market Cap
508.5M
Average Volume 10 Days
8.4K
EPS TTM
€1.90
Shares Outstanding
12.2M
EX-Date
06/2/14
P/E TM
21.9x
Dividend
€0.50
Dividend Yield
1.20%
Request Investor Kit
GBT:FP Advanced Stock Chart

Related News

No related news articles were found.

guerbet (GBT) Related News

No Related News Found

guerbet (GBT) Key Developments

Guerbet Receives FDA's Drug Shortage Assistance Award

Guerbet has received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration for its assistance in preventing or alleviating a drug shortage. Guerbet is being recognized for its efforts related to the shortage of Ethiodol (ethiodized oil) injection, including acquiring the new drug application, submitting several post-approval supplements to restart manufacturing with acceptable compliance records, and to market the product for a well-known and medically necessary indication in the United States. These actions by Guerbet resolved a critical drug shortage affecting patients with cancer. Ethiodol (ethiodized oil) injection, now under the tradename of Lipiodol, is an oil-based radiopaque contrast agent used to image tumors in patients with certain types of cancer. Through the Drug Shortage Assistance Award program, FDA recognizes companies for making a substantial contribution to preventing or alleviating a critical drug shortage. Drug shortages pose a substantial public health threat, delaying, and in some cases even denying, critically needed care for patients. Working with drug manufacturers, the FDA helped prevent over 280 drug shortages in 2012 and 170 in 2013. There were 44 new drug shortages in 2013, down from 117 new drug shortages in 2012. Two key prevention strategies have helped drive this significant decrease in new shortages: 1) early notification and 2) a focus on quality manufacturing. FDA is committed to working with companies, like Guerbet, to prevent and mitigate drug shortages.

Guerbet SA Reports Consolidated Financial Results for the First Half Year Ended June 30, 2014; Revises Financial Guidance for the Full Year 2014

Guerbet SA reported consolidated financial results for the first half year ended June 30, 2014. For the half year, revenue was EUR 202.6 million against EUR 192.4 million a year ago. EBITDA was EUR 32.3 million against EUR 24.2 million a year ago. Current operating income was EUR 19.8 million against EUR 15.2 million a year ago. Net income was EUR 12.7 million against EUR 10.0 million a year ago. Net debt as on June 30, 2014 was EUR 83.3 million against EUR 96.6 million as on June 30, 2013. Based on these first half performances, the group confirms its annual target of EUR 412 million +/- 2% in revenue for 2014 and raises guidance for the current operating margin on reported sales to 9% to 10% compared to initial guidance of 8% to 9%.

Guerbet SA Announces Consolidated Sales Results for the First Quarter Ended March 2014

Guerbet SA announced consolidated sales results for the first quarter ended March 2014. For the period, the company reported sales of EUR 96.6 million, up 6.1% (+8.4% excluding currency effects) from the same period last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GBT:FP €41.68 EUR +0.87

GBT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €110.33 EUR -0.384
Covidien PLC $87.66 USD +1.15
Mallinckrodt PLC $88.99 USD -1.16
 

Industry Analysis

GBT

Industry Average

Valuation GBT Industry Range
Price/Earnings 20.6x
Price/Sales 1.1x
Price/Book 1.9x
Price/Cash Flow 9.9x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

No related news found for this Guerbet.
  • 0
  • 0
  • 0

Get our Stock Market & Financial Investment news alerts in your inbox

Read our full disclaimer and privacy policy